Kiniksa Pharmaceuticals, Ltd.KNSANASDAQ
Loading
SG&A Expense Growth AcceleratingAccelerating
Percentile Rank74
3Y CAGR+4.1%
5Y CAGR-13.0%
Year-over-Year Change
Year-over-year SG&A expense growth
3Y CAGR
+4.1%/yr
Quarterly compound
5Y CAGR
-13.0%/yr
Recent acceleration
Percentile
P74
Within normal range
vs 5Y Ago
0.5x
Contraction
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 15.62% |
| Q3 2025 | 4.78% |
| Q2 2025 | 7.66% |
| Q1 2025 | 7.39% |
| Q4 2024 | -12.64% |
| Q3 2024 | 9.44% |
| Q2 2024 | 9.60% |
| Q1 2024 | 5.29% |
| Q4 2023 | 8.82% |
| Q3 2023 | 18.85% |
| Q2 2023 | 0.72% |
| Q1 2023 | 3.63% |
| Q4 2022 | 13.85% |
| Q3 2022 | 3.51% |
| Q2 2022 | 7.50% |
| Q1 2022 | -5.53% |
| Q4 2021 | 13.38% |
| Q3 2021 | -5.61% |
| Q2 2021 | 6.20% |
| Q1 2021 | 29.08% |
| Q4 2020 | 31.37% |
| Q3 2020 | 23.73% |
| Q2 2020 | 12.37% |
| Q1 2020 | -12.47% |
| Q4 2019 | 14.98% |
| Q3 2019 | -0.11% |
| Q2 2019 | 0.56% |
| Q1 2019 | 4.75% |
| Q4 2018 | 45.29% |
| Q3 2018 | 27.46% |
| Q2 2018 | 16.63% |
| Q1 2018 | 33.45% |
| Q4 2017 | 24.05% |
| Q3 2017 | 5.71% |
| Q2 2017 | 11.40% |
| Q1 2017 | 0.00% |